

Ofelia A Alvarez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9484611/publications.pdf>

Version: 2024-02-01

39
papers

2,251
citations

361296

20
h-index

395590

33
g-index

40
all docs

40
docs citations

40
times ranked

2435
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Liver Fibrosis by Transient Elastography in Children and Young Adults With Sickle Cell Disease With and Without Iron Overload. <i>Journal of Pediatric Hematology/Oncology</i> , 2022, Publish Ahead of Print, .	0.3	0
2	Real-world effectiveness of voxelotor for treating sickle cell disease in the US: a large claims data analysis. <i>Expert Review of Hematology</i> , 2022, 15, 167-173.	1.0	19
3	Accuracy of transcranial Doppler in detecting intracranial stenosis in patients with sickle cell anemia when compared to magnetic resonance angiography. <i>Journal of Clinical Ultrasound</i> , 2022, , .	0.4	1
4	Stroke and stroke prevention in sickle cell anemia in developed and selected developing countries. <i>Journal of the Neurological Sciences</i> , 2021, 427, 117510.	0.3	10
5	First Year Comparison of Sickle Cell Pediatric Cohorts from Haiti and Miami (CSHSCD Multicenter) Tj ETQq1 1 0.784314 rgBT ₈ /Overlook	0.6	0
6	Real-World Experience of Voxelotor for the Management of Complications in Sickle Cell Disease. <i>Blood</i> , 2021, 138, 2052-2052.	0.6	1
7	Successful Quality Improvement Projects to Maximize Prescription Rates and Acceptance of Hydroxyurea Among Patients with Sickle Cell Anemia. <i>Blood</i> , 2021, 138, 2983-2983.	0.6	1
8	Comparative Study of Haiti and Miami Cohorts of Sickle Cell Disease (CSHSCD): Methods, Accomplishments, and Implementation. <i>Blood</i> , 2021, 138, 4054-4054.	0.6	0
9	Newborn Screening for Sickle Cell Disease Using Point-of-Care Testing in Low-Income Setting. <i>Pediatrics</i> , 2019, 144, .	1.0	21
10	Electrical Impedance Characterization of Erythrocyte Response to Cyclic Hypoxia in Sickle Cell Disease. <i>ACS Sensors</i> , 2019, 4, 1783-1790.	4.0	25
11	Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: A SUSTAIN study analysis. <i>American Journal of Hematology</i> , 2019, 94, 55-61.	2.0	78
12	Electrical impedance microflow cytometry with oxygen control for detection of sickle cells. <i>Sensors and Actuators B: Chemical</i> , 2018, 255, 2392-2398.	4.0	45
13	Capacity building and networking to make newborn screening for sickle cell disease a reality in Haiti. <i>Blood Advances</i> , 2018, 2, 54-55.	2.5	2
14	Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial). <i>Blood Advances</i> , 2018, 2, 1969-1979.	2.5	29
15	Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. <i>New England Journal of Medicine</i> , 2017, 376, 429-439.	13.9	599
16	Kidney function of transfused children with sickle cell anemia: Baseline data from the TWITCH study with comparison to non-transfused cohorts. <i>American Journal of Hematology</i> , 2017, 92, E637-E639.	2.0	7
17	Renal Medullary Carcinoma: The Kidney Cancer That Affects Individuals With Sickle Cell Trait and Disease. <i>Journal of Oncology Practice</i> , 2017, 13, 424-425.	2.5	4
18	Effects of hydroxyurea treatment for patients with hemoglobin <sc>SC</sc> disease. <i>American Journal of Hematology</i> , 2016, 91, 238-242.	2.0	54

#	ARTICLE	IF	CITATIONS
19	Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia—TCD With Transfusions Changing to Hydroxyurea (TWITCH): a multicentre, open-label, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2016, 387, 661-670.	6.3	375
20	SUSTAIN: A Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 with or without Hydroxyurea Therapy in Sickle Cell Disease Patients with Sickle Cell-Related Pain Crises. <i>Blood</i> , 2016, 128, 1-1.	0.6	16
21	Genetic Modifiers of White Blood Cell Count, Albuminuria and Glomerular Filtration Rate in Children with Sickle Cell Anemia. <i>PLoS ONE</i> , 2016, 11, e0164364.	1.1	25
22	Renal medullary carcinoma and sickle cell trait: A systematic review. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1694-1699.	0.8	73
23	Quantification of Sickle Cells in the Peripheral Smear as a Marker of Disease Severity. <i>Fetal and Pediatric Pathology</i> , 2015, 34, 149-154.	0.4	16
24	Albuminuria correlates with hemolysis and NAG and KIM-1 in patients with sickle cell anemia. <i>Pediatric Nephrology</i> , 2014, 29, 1997-2003.	0.9	36
25	Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: Results from the SWITCH clinical trial. <i>American Journal of Hematology</i> , 2013, 88, 932-938.	2.0	41
26	Sickle cell disease related mortality in the United States (1999-2009). <i>Pediatric Blood and Cancer</i> , 2013, 60, 1482-1486.	0.8	215
27	Effect of hydroxyurea treatment on renal function parameters: Results from the multicenter placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. <i>Pediatric Blood and Cancer</i> , 2012, 59, 668-674.	0.8	94
28	Durable immune response to inactivated H1N1 vaccine is less likely in children with sickle cell anemia receiving chronic transfusions. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1280-1283.	0.8	15
29	Stroke with transfusions changing to hydroxyurea (SWITCH): A phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1011-1017.	0.8	66
30	Increased prevalence of false positive hemoglobinopathy newborn screening in premature infants. <i>Pediatric Blood and Cancer</i> , 2011, 57, 1039-1043.	0.8	12
31	Renal Function in Infants with Sickle Cell Anemia: Baseline Data from the BABY HUG Trial. <i>Journal of Pediatrics</i> , 2010, 156, 66-70.e1.	0.9	109
32	Adherence to Deferasirox in Children and Adolescents With Sickle Cell Disease During 1-year of Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2009, 31, 739-744.	0.3	31
33	Short-term follow-up of patients with sickle cell disease and albuminuria. <i>Pediatric Blood and Cancer</i> , 2008, 50, 1236-1239.	0.8	43
34	Plasma Endothelin-1 and Leukocyte Microparticles Increase during Pain Episode in Patients with Sickle Cell Disease. <i>Blood</i> , 2007, 110, 3807-3807.	0.6	0
35	Early blood transfusions protect against microalbuminuria in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2006, 47, 71-76.	0.8	74
36	Serum cystatin C levels in children with sickle cell disease. <i>Pediatric Nephrology</i> , 2006, 21, 533-537.	0.9	33

#	ARTICLE	IF	CITATIONS
37	Thoracic Lymphangiomas in a Child. <i>Journal of Pediatric Hematology/Oncology</i> , 2004, 26, 136-141.	0.3	69
38	Evaluation of Chronic Transfusion (Tx) Practices in Children with Sickle Cell Disease (SCD): A Survey of STOP II Investigators.. <i>Blood</i> , 2004, 104, 3732-3732.	0.6	4
39	Is Screening for Microalbuminuria Warranted in Children with Sickle Cell Hemoglobinopathies?.. <i>Blood</i> , 2004, 104, 1674-1674.	0.6	0